Peptides
Mechanisms, research, benefits, limitations, and emerging applications.
59 articles in Peptides
GLP-1 vs Growth-Hormone Peptides: Different Goals, Different Evidence
Two popular peptide categories with wildly different levels of proof behind them.
Read →Injection Technique and Peptides: What the Research Suggests
Site, depth, and rotation — the practical details that affect both safety and absorption.
Read →The Economics of Peptide Research: Why Trials Lag
Unpatentable molecules don't fund Phase 3 trials. That single fact explains much of the evidence gap.
Read →Bioregulator Peptides and Aging: A Skeptical Review
A careful look at one of the most overclaimed corners of the longevity-peptide market.
Read →Peptide Tolerance and Desensitization, Explained
Why some peptides stop working over time, and what receptor biology says about it.
Read →BPC-157: Separating the Evidence from the Hype
BPC-157 is one of the most talked-about peptides online. The animal data is genuinely interesting. The human data is almost nonexistent. Both things are true.
Read →Tesofensine: Appetite, Weight, and the Open Questions
A triple-reuptake inhibitor studied for obesity, with efficacy and safety questions still unresolved.
Read →What Phase a Peptide Is In, and Why It Matters
Preclinical, Phase 1, Phase 3 — the single most useful question to ask about any compound.
Read →How Peptides Signal: Receptors, Cascades, and Effects
From binding to biological effect — the chain of events behind every peptide claim.
Read →Peptides and Cancer Risk: Untangling a Complicated Question
Growth-signaling peptides raise legitimate questions that the marketing rarely addresses.
Read →The Real Risks of Sourcing Peptides Online
Contamination, mislabeling, and dosing errors — the practical dangers beyond the biology.
Read →Why Peptide Dosing in Studies Rarely Matches Marketing
The doses in the research and the doses on the label are often worlds apart.
Read →Adipotide: A Cautionary Tale in Peptide Development
A fat-loss peptide that worked — and showed why 'it works in mice' isn't enough.
Read →Humanin: A Mitochondrial-Derived Peptide Worth Watching
Early but serious science on a peptide tied to metabolic and neuroprotective pathways.
Read →Growth Hormone Secretagogues: Do They Beat Direct HGH?
Stimulating your own GH versus injecting it — the trade-offs the marketing skips.
Read →SS-31 (Elamipretide): The Mitochondrial Peptide in Trials
A genuinely promising compound moving through real clinical trials — a useful benchmark for the field.
Read →Compounded Peptides and the FDA's Shifting Stance
The regulatory ground is moving under the compounded-peptide market. Here's the current picture.
Read →5-Amino-1MQ: NNMT Inhibition and the Hype Cycle
A metabolic target with interesting biology and a familiar gap between promise and proof.
Read →Peptides for Skin: Topical vs Injected Evidence
Where cosmetic peptides have a real case, and where the claims sprint past the data.
Read →LL-37: The Antimicrobial Peptide Behind the Buzz
A real part of human immunity, increasingly marketed in ways the evidence doesn't support.
Read →Creatine vs Peptides for Recovery: Where the Evidence Stands
One is among the most-studied supplements ever; the others mostly aren't. The contrast is instructive.
Read →The Placebo Problem in Peptide Research
Why uncontrolled peptide anecdotes are so easy to believe and so hard to trust.
Read →Collagen Peptides: One of the Few With Decent Human Data
An outlier in the peptide world — modest but real evidence for skin and connective tissue.
Read →Peptide Stacking: Why Combining Compounds Multiplies Unknowns
Each added peptide doesn't add risk linearly — it compounds the uncertainty.
Read →BPC-157 and Gut Health: A Closer Look at the Claims
The gut-protection story is where BPC-157's animal data is strongest — and the human gap widest.
Read →Hexarelin: The Forgotten Growth-Hormone Peptide
A potent secretagogue sidelined by tolerance and side effects — and what it taught researchers.
Read →GHRP-6 vs GHRP-2: Comparing the Older Secretagogues
The first-generation GH peptides, their quirks, and why newer options often replaced them.
Read →BPC-157 for Tendons: What the Animal Studies Found
Reproduced rodent results, zero controlled human trials. The honest state of the evidence.
Read →Reconstitution and Storage: The Science of Peptide Stability
Why handling matters, what degrades a peptide, and how that affects whatever you're measuring.
Read →Receptor Agonists vs Antagonists: A Plain-Language Primer
The vocabulary you need to actually understand how a peptide is supposed to act.
Read →Peptide Side Effects: What the Safety Data Actually Shows
Beyond the marketing, what's known — and badly under-studied — about peptide safety.
Read →Why Most Peptide Claims Outrun the Evidence
The structural reasons the marketing is always years ahead of the science.
Read →Are Peptides Legal? The Regulatory Landscape in 2026
A clear-eyed look at the gray zone between approved drugs, research chemicals, and compounding.
Read →The Difference Between Peptides and Proteins, Explained
Where one ends and the other begins — and why the distinction matters for how they behave.
Read →Research Peptides and Purity: What 'For Research Use Only' Means
The label isn't a marketing quirk — it's a signal about testing, oversight, and what you're really buying.
Read →Peptide Half-Life, Explained: Why Dosing Frequency Varies
Half-life is the hidden variable behind every dosing schedule. Here's what it actually means.
Read →Animal Data vs Human Data: The Peptide Translation Gap
Why so many peptides that heal rats do nothing measurable in people.
Read →Oral vs Injectable Peptides: Why the Route Matters
The delivery route shapes everything — dose, effect, and whether a product can work at all.
Read →How to Read a Peptide Study Without Getting Fooled
A practical filter for separating a meaningful finding from a press-release headline.
Read →Kisspeptin: The Peptide Reshaping Reproductive Research
A genuine area of active clinical science — and a useful contrast to the hype-driven peptide market.
Read →Peptide Bioregulators: Evidence or Marketing?
Khavinson peptides promise organ-specific rejuvenation. The evidence base is a cautionary tale in itself.
Read →Follistatin and Muscle Growth: What the Science Says
Blocking myostatin sounds like a shortcut to muscle. The biology — and the risks — are more complicated.
Read →AOD-9604: The Fat-Loss Peptide That Didn't Pan Out
A fragment of growth hormone once trialed for obesity. The results explain why you don't hear about it from doctors.
Read →How Peptides Are Absorbed: The Bioavailability Problem
Why most peptides are injected, why oral versions are hard, and what that means for the products you see online.
Read →MOTS-c: The Mitochondrial Peptide, Explained
A mitochondrial-derived peptide with intriguing metabolic effects in animals and a thin human record.
Read →DSIP (Delta Sleep-Inducing Peptide): Does It Help Sleep?
Named for what it was supposed to do. Decades later, the sleep evidence remains surprisingly weak.
Read →Epitalon: Sorting the Longevity Claims From the Evidence
A peptide marketed for telomeres and lifespan, resting almost entirely on small, hard-to-replicate studies.
Read →Semax: Nootropic Peptide or Overstated Hype?
Marketed for focus and neuroprotection, Semax has a real research history — mostly outside Western journals.
Read →Selank and Anxiety: A Look at the Limited Human Data
A Russian-developed anxiolytic peptide with some clinical use and very little independent replication.
Read →Melanotan II: Why the Tanning Peptide Carries Real Risks
The 'barbie drug' delivers tanning and worse. A look at why dermatologists keep warning against it.
Read →PT-141 (Bremelanotide): The Evidence on Libido and Arousal
An approved drug for low desire in women — and a popular off-label experiment. What the trials show.
Read →Thymosin Beta-4 and Tissue Repair: Reading the Preclinical Data
The molecule behind TB-500 shows real promise in animals. Translating that to humans is the unfinished work.
Read →Tesamorelin: The One Peptide With Real FDA Approval
Approved for HIV-associated lipodystrophy, tesamorelin is a rare peptide with genuine clinical-trial backing.
Read →Thymosin Alpha-1: What We Know About the Immune Peptide
Used clinically in some countries for immune support, with a research base that's larger than most peptides — but still mixed.
Read →TB-500: What the Research Does and Doesn't Show
Thymosin beta-4's fragment is sold for recovery and repair. The preclinical signal is real; the human evidence is almost absent.
Read →Ipamorelin: A Closer Look at the Growth-Hormone Secretagogue
A selective GH secretagogue with a cleaner side-effect profile on paper — but limited long-term human data.
Read →CJC-1295 and Ipamorelin: How the Combo Is Supposed to Work
Why these two growth-hormone secretagogues are stacked, and what the evidence does and doesn't support.
Read →GHK-Cu: The Copper Peptide Behind the Skin Claims
GHK-Cu has more credible topical evidence than most peptides — and far thinner support for the systemic claims.
Read →Sermorelin vs CJC-1295: Comparing Two GH Secretagogues
Both nudge your own growth hormone. The difference is half-life, dosing, and how much we actually know.
Read →